Endocrine and metabolic adverse effects of immune checkpoint inhibitors: an overview (what endocrinologists should know)

Immune checkpoint inhibitors (ICIs) are novel anticancer agents, recently introduced with the aim of boosting the immune response against tumors. ICIs are monoclonal autoantibodies that specifically target inhibitory receptors on T cells: cytotoxic T lymphocyte antigen 4 (CTLA4), programmed death 1...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of endocrinological investigation 2019-07, Vol.42 (7), p.745-756
Hauptverfasser:	Ruggeri, R. M., Campennì, A., Giuffrida, G., Trimboli, P., Giovanella, L., Trimarchi, F., Cannavò, S.
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic Agents, Immunological - adverse effects Antitumor agents Apoptosis Autoantibodies Cancer Cell Cycle Checkpoints - drug effects Corticosteroids CTLA-4 protein Cytotoxicity Diabetes mellitus Drug-Related Side Effects and Adverse Reactions - etiology Endocrine System Diseases - chemically induced Endocrinology Humans Immune checkpoint inhibitors Immunosuppression Immunosuppressive agents Lymphocytes T Medicine Medicine & Public Health Metabolic Diseases Metabolic Diseases - chemically induced Metabolism Neoplasms - drug therapy PD-1 protein Prognosis Review Article Thyroid Thyroid diseases Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!